Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Currency in USD	2025
Operating Income	45.11 Million
Income Before Tax	-68.09 Million
Income Tax Expense	0.00
Net Income	-68.09 Million
Eps	-3.22
Epsdiluted	-3.22
Weighted Average Shs Out	167.21 Million
Weighted Average Shs Out Dil	167.21 Million
Research And Development Expenses	101.58 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	22.61 Million
Interest Expense	56.85 Million
Interest Income	16.50 Million
Net Interest Income	-40.36 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	539.17 Million
Ebitda	67.73 Million
Source	edgar
Ebit	-11.23 Million

Caris Life Sciences, Inc. Annual Reports (10-K)